Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

zed, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy. Up to four dose levels may be evaluated in a serial ascending fashion. Once an optimal or maximal dose is identified, additional patients will be added to confirm clinical observations.

"The clinical trial will be conducted at multiple cancer centers in the United States," said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer at Lexicon. "The clinical trial sites will include The University of Texas M.D. Anderson Cancer Center in Houston, Texas; the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Hematology Oncology Services of Little Rock, Arkansas."

LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

About LX1032

LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakdown product, 5-HIAA, is a biomarker used in the diagnosis of the condition. In preclinical studies, LX1032 reduced peripheral serotonin and urinary 5-HIAA levels in several different species without affecting serotonin levels in the brain. In Phase 1 clinical studies, LX1032 reduced serotonin levels and urinary 5-HIAA in healthy volunteers consistent with preclinical results. LX1032 is being developed for the treatment of gastrointestinal symptoms associated with carcinoid syndrome in patients who
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Investor-Edge has initiated coverage on ... ), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), ... Pharmaceuticals Inc. (NASDAQ: PPHM ), and StemCells ... can be accessed at: http://investor-edge.com/register . ... on a positive note as the Dow Jones Industrial ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2
... Guide, ,I. Description ,II. Product Components ... ,IV. Protocol for Extraction of DNA from Whole Blood ... Whole Blood ,VI. Quantification of Amplified Products ... Application Data , References , Contact Information ...
... ,I. Description ,II. Product Components ,III. ... Protocol for Extraction of DNA from Blood Card ... Card ,VI. Quantification of Amplified Products ,VII. ... , References , Contact Information , , ,Application ...
... , , ... , , , Mutations ... of the colon, pancreas, liver, spleen, stomach or lungs. The,CDKN2A/P16 gene is ... which point mutation is present,in patient tissue samples. Freshly frozen tumor sections ...
Cached Biology Technology:Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 2Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 3Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 4Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 5Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 6Protocol for GenomePlex Whole Genome Amplification from Blood Card 2Protocol for GenomePlex Whole Genome Amplification from Blood Card 3Protocol for GenomePlex Whole Genome Amplification from Blood Card 4Protocol for GenomePlex Whole Genome Amplification from Blood Card 5Protocol for GenomePlex Whole Genome Amplification from Blood Card 6Mutation detection for the,K- rasand P16 genes 2Mutation detection for the,K- rasand P16 genes 3Mutation detection for the,K- rasand P16 genes 4Mutation detection for the,K- rasand P16 genes 5Mutation detection for the,K- rasand P16 genes 6
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... A tiny wasp that lays its eggs under the ... most diverse groups of insects on Earth. Now researchers ... thought. (To see an audio slide show on ... By combining ecological and genetic data with the painstaking ...
... risk during cardiac procedures. Doctors performing heart surgery also ... IAEA is helping to raise awareness of threats, through ... X-ray imaging systems. The issue of radiation protection ... of lengthy angioplasty and other cardiac interventions performed under ...
... insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts ... treatment, said researchers at Baylor College of Medicine in a ... Journal of Clinical Oncology. The finding gives impetus to ... various tumors. "These findings come at a critical time," ...
Cached Biology News:Diversity among parasitic wasps is even greater than suspected 2Diversity among parasitic wasps is even greater than suspected 3Protecting those who heal 2Growth factor predicts poor outcome in breast cancer 2
6B9...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Biology Products: